Reviva Pharmaceuticals Holdings Stock Price on October 3, 2024
| RVPH Stock | USD 1.78 0.14 8.54% |
Below is the normalized historical share price chart for Reviva Pharmaceuticals Holdings extending back to October 18, 2018. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Reviva Pharmaceuticals stands at 1.78, as last reported on the 25th of December, with the highest price reaching 1.84 and the lowest price hitting 1.54 during the day.
If you're considering investing in Reviva Stock, it is important to understand the factors that can impact its price. Reviva Pharmaceuticals appears to be very risky, given 3 months investment horizon. Reviva Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of 0.0937, which implies the firm had a 0.0937% return per unit of risk over the last 3 months. By analyzing Reviva Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.97% is justified by implied risk. Please evaluate Reviva Pharmaceuticals' Risk Adjusted Performance of 0.0918, semi deviation of 8.69, and Coefficient Of Variation of 968.56 to confirm if our risk estimates are consistent with your expectations.
Reviva Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 18th of October 2018 | 200 Day MA 1.7039 | 50 Day MA 1.3718 | Beta (0.06) |
Reviva |
Sharpe Ratio = 0.0937
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RVPH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.4 actual daily | 92 92% of assets are less volatile |
Expected Return
| 0.97 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Reviva Pharmaceuticals is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Reviva Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 8.3482 | Book Value 0.205 | Enterprise Value 70.9 M | Enterprise Value Ebitda (6.00) | Shares Float 26.7 M |
Related Headline
Caribou Biosciences Headline on 3rd of October 2024
Acquisition by Rachel Haurwitz of 10000 shares of Caribou Bi... by Rachel Haurwitz
Filed transaction by Caribou Biosciences Director, Officer: President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Reviva Pharmaceuticals Valuation on October 3, 2024
It is possible to determine the worth of Reviva Pharmaceuticals on a given historical date. On October 3, 2024 Reviva was worth 1.27 at the beginning of the trading date compared to the closed value of 1.22. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Reviva Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Reviva Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Reviva Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Reviva Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 1.41 | 1.46 | 1.27 | 1.28 | 228,884 | |
10/03/2024 | 1.27 | 1.30 | 1.22 | 1.22 | 214,373 |
| 1.25 | 1.28 | 1.15 | 1.25 | 135,406 |
| Backtest Reviva Pharmaceuticals | | | Reviva Pharmaceuticals History | | | Reviva Pharmaceuticals Valuation | Previous | Next |
Reviva Pharmaceuticals Trading Date Momentum on October 3, 2024
| On October 04 2024 Reviva Pharmaceuticals Holdings was traded for 1.25 at the closing time. The top price for the day was 1.28 and the lowest listed price was 1.15 . The trading volume for the day was 135.4 K. The trading history from October 4, 2024 was a factor to the next trading day price growth. The trading delta at closing time against the next closing price was 2.46% . The trading delta at closing time against the current closing price is 2.46% . |
Reviva Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Reviva Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Reviva financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Reviva Pharmaceuticals Stock history
Reviva Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Reviva is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Reviva Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Reviva Pharmaceuticals stock prices may prove useful in developing a viable investing in Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. Reviva Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.
Reviva Pharmaceuticals Stock Technical Analysis
Reviva Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Reviva Pharmaceuticals Period Price Range
Low | December 25, 2024
| High |
0.00 | 0.00 |
Reviva Pharmaceuticals Holdings cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Reviva Pharmaceuticals December 25, 2024 Market Strength
Market strength indicators help investors to evaluate how Reviva Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Reviva Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Reviva Pharmaceuticals stock market strength indicators, traders can identify Reviva Pharmaceuticals Holdings entry and exit signals to maximize returns
Reviva Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Reviva Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Reviva Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Reviva to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0918 | |||
| Jensen Alpha | 1.06 | |||
| Total Risk Alpha | 0.5979 | |||
| Sortino Ratio | 0.1013 | |||
| Treynor Ratio | (1.99) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Reviva Stock analysis
When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |